Effects of a ketamine metabolite on synaptic NMDAR function
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AP5 (50 μM) and ketamine (50 μM) produced a 90-100% reduction in charge transfer indicating that AP5 and ketamine are more potent at inhibiting NMDAR-mEPSCs relative to (2R,6R)-HNK.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Suzuki et al., 2017
In the citing paper
“NMDAR-mEPSCs were concentration-dependently and rapidly (within 10 minutes) attenuated by (2R,6R)-HNK with 10 μM having no effect and 50 μM producing an ~40% reduction in charge transfer.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Suzuki et al., 2017
In the citing paper
“At the synaptic level, eEF2K inhibition increases AMPAR-mediated miniature EPSC amplitudes and induces rapid synaptic scaling, closely matching the profile seen after ketamine or 2R,6R-HNK [146,149,150].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [150]
In the citing paper
“Suzuki et al. (2017) 129 recently confirmed that (2R,6R)-HNK does not functionally inhibit NMDAR-mEPSCs at 10 μM 129.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [129]
In the citing paper
“These authors also reported that at a higher concentration (50 μM), (2R,6R)-HNK induces a modest (~40%) inhibition of NMDAR-mEPSCs 129, which could result in off-target effects of this metabolite at high doses.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [129]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Self-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
THE ROUTE OF ABSORPTION OF INTRAPERITONEALLY ADMINISTERED COMPOUNDS
LUKAS, G., BRINDLE, S. D., & GREENGARD, P. (1971) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28988-1 · Cited by 388
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283
Self-citationGideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
Self-citationAtasoy, D., Ertunc, M., Moulder, K. L., Blackwell, J., Chung, C., Su, J., & Kavalali, E. T. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2432-08.2008 · Cited by 200
Self-citationMoaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176
Memantine binding to a superficial site on NMDA receptors contributes to partial trapping
Kotermanski, S. E., Wood, J. T., & Johnson, J. W. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.176297 · Cited by 92
Cited by
Items 101–184 of 184
Psychedelics, entactogens and psychoplastogens for depression and related disorders
Hoyer, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70088 · Cited by 18
“However, others have suggested that (2S,6S)- HNK has antidepressant effects and that both enantiomers act via NMDA receptors (Suzuki et al., 2017); this has been disputed by Zanos et al (Zanos et al., 2017).”
Han, Y.-X., Reddy, K. M., & Corey, E. J. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b02498 · Cited by 18
Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
Chaki, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx120 · Cited by 17
Antidepressant Effects of (S)-Ketamine through a Reduction of Hyperpolarization-Activated Current I
Kim, C. S., & Johnston, D. (2020) · iScience · doi:10.1016/j.isci.2020.101239 · Cited by 16
“, reported that 50 mM (R,S)-ketamine or (2R,6R)-HNK blocks synaptic NMDA receptors (Suzuki et al., 2017).”
BackgroundResolvins as potential candidates for the treatment of major depressive disorder
Deyama, S., Minami, M., & Kaneda, K. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.05.002 · Cited by 19
Mechanisms of the Antidepressant Effects of Ketamine Enantiomers and Their Metabolites
Ide, S., & Ikeda, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.07.018 · Cited by 18
Jurásek, B., Králík, F., Rimpelová, S., Čejka, J., Setnička, V., Ruml, T., Kuchař, M., & Kohout, M. (2018) · New Journal of Chemistry · doi:10.1039/c8nj03107j · Cited by 21
The role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
“27 These two inconsistent studies used different concentrations of (2R, 6R)- HNK to investigate NMDAR inhibition.”
BackgroundInfluentialElmer, G. I., Tapocik, J. D., Mayo, C. L., Zanos, P., & Gould, T. D. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172973 · Cited by 17
“In contrast, (2R,6R)-HNK has limited to no affinity/potency to inhibit the NMDAR at antidepressant-relevant concentrations (Lumsden et al., 2019; Moaddel et al., 2013; Morris et al., 2017; Suzuki et al., 2017; Zanos et al., 2016).”
BackgroundCYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors
Abbott, J. A., & Popescu, G. K. (2020) · Molecular Pharmacology · doi:10.1124/mol.120.119784 · Cited by 17
“This result is consistent with the previous observation that both KET and HNK block spontaneous synaptic currents mediated by NMDA receptors in hippocampal neurons (Suzuki et al., 2017), yet when the drugs are coapplied with subsaturating levels of the synthetic partial agonist NMDA, only KET (10 mM) reduced whole-cel…”
BackgroundResultStructural prediction of GluN3 NMDA receptors
Liu, Y., Shao, D., Lou, S., & Kou, Z. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1446459 · Cited by 17
Asrar, B., Ali, N. S., Ali, I., & Naveed, M. (2025) · Scientific Reports · doi:10.1038/s41598-024-82302-0 · Cited by 16
Brown, K. A., Ajibola, M. I., & Gould, T. D. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02085-4 · Cited by 15
“…occur at concentrations much greater than those required for antidepressant-like effects (e.g., HNK IC 50 = 211.9 µM for SC-CA1 NMDAR-mediated fEPSP; IC 50 = 63.7 µM for CA1 principal cell mEPSC amplitude [21, 32]; NMDAR open channel block at 50 µM but not 10 µM in hippocampal neuron culture [65]).”
InfluentialA molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine
Elmeseiny, O. S. A., & Müller, H. K. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107081 · Cited by 14
Dagher, M., Cahill, C. M., & Andrews, A. M. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100046 · Cited by 16
“…NMDA receptors on GABAergic neurons leading to (2) a glutamate surge that activates AMPA receptors, resulting in (3) increased BDNF release and mTOR signaling, which increases protein synthesis and AMPA receptor cycling (Li et al, 2010; Abdallah et al, 2015; Suzuki et al, 2017; Kim et al, 2021).”
Ye, L., Xiao, X., Xu, Y., Zheng, C., Chen, S. X., Luo, T., Li, Z., Du, Y., Yuan, Y., Li, L., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108984 · Cited by 15
Li, X., Saiyin, H., Chen, X., Yu, Q., Ma, L., & Liang, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01864-5 · Cited by 16
Novel rapid-acting antidepressants: molecular and cellular signaling mechanisms
Thomas, A. M., & Duman, R. S. (2017) · Neuronal Signaling · doi:10.1042/ns20170010 · Cited by 14
“However, recent evidence from another laboratory indicates that HNK may in fact act at NMDARs, although at higher doses [40].”
Faccio, A. T., Rupérez, F. J., Singh, N., Angulo, S., Tavares, M. F. M., Bernier, M., Barbas, C., & Wainer, I. W. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.03.008 · Cited by 14
Widman, A. J., & McMahon, L. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.001 · Cited by 15
Spontaneous neurotransmission: A form of neural communication comes of age
Kavalali, E. T. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24207 · Cited by 16
Self-citationWegman-Points, L., Pope, B., Zobel-Mask, A., Winter, L., Wauson, E., Duric, V., & Yuan, L.-L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.590221 · Cited by 12
“Recent work provided evidence that HNK on its own is sufficient for the RAAD effect in rodents, although subsequent work has challenged this assertion[7, 23, 24].”
ResultJiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
“In brain slices in vitro , HNK can block NMDARs at 50 μM [157] but not at 10 μM [55,157].”
BackgroundMethodRole of group II metabotropic glutamate receptors in ketamine's antidepressant actions
Onisiforou, A., Georgiou, P., & Zanos, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173531 · Cited by 12
Li, X., Liu, S., Huo, S.-Y., Pu, L.-Q., Li, J.-J., Bai, W., Yang, Y., & Shao, J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s345884 · Cited by 11
“Its anesthetic and analgesic properties are typically attributed to its direct inhibition of N-methyl-D-aspartate receptor (NMDAR).(9) Not only that but it also has affinity for many other receptors, including γ-aminobutyric acid, dopamine, serotonin, opioid and cholinergic receptors, as well as voltage-gated sodium a…”
BackgroundHe, Y., Lin, Q., Lyu, D., Tang, N., & Womack, A. W. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.268929 · Cited by 10
“Because a robust increase in cell death occurs during ketamine withdrawal, scientists have proposed that the apoptosis is triggered by compensatory up-regulation of NMDAR subunit 1 (Wang et al., 2005, 2006; Suzuki et al., 2017; Nagels et al., 2018).”
Wang, Y., Xu, J., Zhou, X., Che, L., Qiu, M., Liu, Y., Gao, M., & Yang, Z. (2025) · Advanced Science · doi:10.1002/advs.202516024 · Cited by 13
Rahman, S. U., Hao, Q., He, K., Li, Y., Yang, X., Ye, T., Ali, T., Zhou, Q., & Li, S. (2020) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201900094 · Cited by 9
Synaptic basis of rapid antidepressant action
Kavalali, E. T., & Monteggia, L. M. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01898-6 · Cited by 7
“Overall, these data demonstrated that (2R,6R)-HNK inhibits synaptic NMDARs and subsequently elicits the same signal transduction pathway previously associated with NMDAR inhibition by ketamine [ 11 ].”
Self-citationGeiger, Z., VanVeller, B., Lopez, Z., Harrata, A. K., Battani, K. A., Wegman‐Points, L., & Yuan, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.678978 · Cited by 8
“It should be noted, however, (2R, 6R)-HNK at 50 μM does block synaptic NMDAR function (Suzuki et al., 2017), indicating the complexity of the mechanism of ketamine actions and again highlighting its critical dosage dependence.”
BackgroundBelloch, F. B., Cortés-Erice, M., Herzog, É., Zhang, X. M., Diaz-Perdigón, T., Puerta, E., & Tordera, R. M. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110640 · Cited by 8
TRKB interaction with PSD95 is associated with latency of fluoxetine and 2R,6R‐hydroxynorketamine
Fred, S. M., Moliner, R., Antila, H., Engelhardt, K., Schlüter, O. M., Casarotto, P. C., & Ċastrén, E. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15952 · Cited by 7
“The NMDARindependent actions of RHNK were challenged by another study, showing that 50-μM RHNK can block the NMDARs in vitro (Suzuki et al., 2017).”
BackgroundXiong, H., Li, L., Li, Y., Chen, Y., Leng, J., & Chen, T. (2026) · Brain and Behavior · doi:10.1002/brb3.71408 · Cited by 6
“Notably, modulation of ACC activity and functional connectivity is a pivotal mechanism underlying ketamine’s rapid mood-and pain-modifying effects (Suzuki et al. 2017 , N. Li et al. 2010 ; Krystal et al. 2024 ).”
Ketamine for Major Depressive Disorder
Costi, S. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_453 · Cited by 6
Mitsi, V., Ruiz, A., Polizu, C., Farzinpour, Z., Ramakrishnan, A., Serafini, R. A., Parise, E. M., Floodstrand, M., Sial, O. K., Gaspari, S., et al. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.123.000753 · Cited by 6
“These findings have stimulated research on the mechanisms by which ketamine and other fast-acting medications affect synaptic function (Autry et al., 2011; Zanos et al., 2016; Suzuki et al., 2017).”
BackgroundThe rapid‐onset antidepressant effect of ketamine: More surprises?
Raffa, R. B., Pergolizzi, J. V., & Taylor, R. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12656 · Cited by 5
Synaptic Plasticity in the Hippocampus
Bliss, T., Collingridge, G. L., Cooke, S. F., Georgiou, J., & Morris, R. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190065324.003.0010 · Cited by 5
Masud, S. B., Jenkins, C., Hussey, E. K., Elkin-Frankston, S., Mach, P. M., Dhummakupt, E. S., & Aeron, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255240 · Cited by 8
Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions
Nguyen, T. M. L., Guilloux, J., Defaix, C., Mendez‐David, I., Etting, I., Alvarez, J., McGowan, J. C., Highland, J. N., Zanos, P., Lovett, J., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110065 · Cited by 5
Liu, H., Wu, X., Chen, J., & Fang, Y. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00794-6 · Cited by 4
“However, a later study has indicated that blocking NMDARs is the likely effect of (2R,6R)-HNK in its antidepressant action [11].”
BackgroundPark, D., Lee, G., Kim, B. S., Seong, M., & Kim, J. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02288-9 · Cited by 4
“Despite its minimal NMDAR-blocking activity, (2 R,6 R)-HNK produces rapid and sustained antidepressant effects in preclinical models [123].”
Insights for the Next Generation of Ketamine for the Treatment of Depressive Disorder
Martins, A. C. F., Badenoch, B., & Gomes, R. D. S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02467 · Cited by 4
Dysregulated Protein Synthesis in Major Depressive Disorder
Heaney, C. F., & Raab‐Graham, K. F. (2019) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190686307.013.3 · Cited by 4
Hutt, A., & Wahl, T. (2021) · Journal of Physics Complexity · doi:10.1088/2632-072x/ac4004 · Cited by 3
“For ketamine, it has been argued that it causes a decrease in the decay time constant of glutamatergic neurons [44], which we model here as an decrease of τ e .”
BackgroundNeurochemical Signaling in Depression: Impact of Target-Based Pharmaceuticals
Sharma, B., & Khushboo (2022) · Current Drug Therapy · doi:10.2174/1574885517666220817122840 · Cited by 4
Szybko działające antydepresanty — punkt zwrotny w leczeniu depresji?
Gabryel, B., Basiaga, B., Bednarz, K., & Żądecka-Kobiałka, K. (2023) · Psychiatria · doi:10.5603/psych.2022.0007 · Cited by 2
Qian, J.-J., Zhang, F., Chen, W., Zhu, B.-L., Jin, F.-Y., Shen, J., Jiang, B., & Fan, H. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110632 · Cited by 2
Coutellier, L. D., Musazzi, L., & Pavlovic, Z. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_4 · Cited by 2
Chaki, S., & Yamaguchi, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00011-6 · Cited by 2
Synaptic plasticity in fronto-insular circuits underlying stress susceptibility and resilience
Rocks, D., & Liston, C. M. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.12.006 · Cited by 2
“Other studies indicate that ketamine may also act to promote synapse formation through an active metabolite, hydroxynorketamine (Suzuki et al., 2017; Zanos et al., 2016), and through direct binding to TrkB (Casarotto et al., 2021).”
Tingting, J. I. N., Ng, H. L. L., Jiang, Y., Ho, I. H. T., Zou, Y., Li, Q., Zhang, L., Chen, H., Wang, J., Zhou, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2261014/v1 · Cited by 2
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 2
(2R,6R)-Hydroxynorketamine, A Metabolite of Ketamine: The Antidepressant Actions and the Mechanisms
Fukumoto, K., & Duman, R. S. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_2 · Cited by 2
Mechanism of antidepressant action of ketamine and differences between its two enantiomers
Zhan, J., Zhang, Y., Tian, H., Zhu, X., Guo, M., Qiu, Z., & Xia, Z. (2025) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2025.06.001 · Cited by 1
“177 A study delving into the level of anti-depressant binding to the transmembrane structural domain of TRKB found that (2 R,6 R)-HNK could displace fluoxetine from binding to TrkB and was much more potent than the displacements of (2S,6S)- HNK, which directly bound to TrkB and triggered signaling…”
Brown, K. A., Morris, P. J., Thomas, C. J., & Gould, T. D. (2026) · Journal of Neuroscience · doi:10.1523/jneurosci.0958-25.2026 · Cited by 1
Liu, J.-M., Zhang, Y., Guo, F., Li, B.-W., Chen, H., Mo, Y., Kong, J., Tan, X., Wu, W., & Cao, X. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03874-1 · Cited by 1
Synaptic Modulation in the Effect of Ketamine
Okada, D. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_5 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Spatiotemporal terahertz modulation enhances NMDAR-mediated miniature EPSCs
Jiang, S., Zhong, Y., Chen, P., Wang, A., Zhu, J., Li, Y., & Zhu, Z. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-08207-8 · Cited by 2
“To record NMDA-mediated miniature excitatory postsynaptic currents (mEPSCs), artificial cerebrospinal fluid (ACSF) without Mg² ⁺ (Mg² ⁺ -free ACSF) was utilized 5,74,75 .”
Chen, B. K., LaGamma, C. T., Xu, X., Deng, S., Brachman, R. A., Suckow, R. F., Cooper, T. B., Landry, D. W., & Denny, C. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/712752 · Cited by 1
“On the other hand, (2R,6R)-HNK is hypothesized to act preferentially on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), although some evidence suggests that this action may be dose-specific and may not have a direct effect on depressive-like behavior (19, 36-38).”
BackgroundImpact of open channel blockers on the surface dynamics and organization of NMDA receptors
Fernandes, A. (2020) · theses.fr (ABES) · doi:10.70675/d12c14b2z7a80z4668z9c48z8e2c0e41c009 · Cited by 2
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
The Rise of Ketamine in Clinical Practice
Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180314-02
The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Sanacora, G., Kitay, B. M., & Wilkinson, S. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00035-4
Hmaied, C., Koulchitsky, S., Gladwyn-Ng, I. E., & Seutin, V. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.19.255794
“One or several metabolites (in particular 2R-6R hydroxynorketamine [HNK]) probably contribute to this effect, perhaps by acting on a different target (Zanos et al., 2016, but see Suzuki et al., 2017).”
BackgroundRapid-Acting Antidepressant Effect of Ketamine and Its Clinical Application
Kim, Y., & Shin, C. (2018) · 신경정신의학 · doi:10.4306/jknpa.2018.57.2.108
Kano, M., & Watanabe, T. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733168960.793562671
Möhler, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735371319.793560281
Möhler, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732838229.793560282
Hen, R. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733878336.793552589
Duman, R. S. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732838229.793546101
Zhang, M., Zheng, L., Chen, J., & Zheng, Y. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110294
Ketamine - mechanisms of action as an antidepressant
Gębik, B., Bliźniewska-Kowalska, K. M., & Gałecki, P. (2026) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/202128
“This may underline some additional dose-dependent properties of this metabolite in its high concentrations [68].”
Analgesia with Ketamine and Its Metabolites: Mechanisms and Effects
Boucherie, D. E., Schrantee, A., Hollmann, M. W., & Brinkman, D. J. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_10
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Ketamine and its metabolites—Mechanism of action
Kneebusch, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00010-2
Neuropsychological mechanisms of ketamine antidepressant effect
Costi, S. (2025) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-wvydgvb7o
Atasoy-Rodriguez, I. L., Johnson, K. W., Patel, K., Arain, H., Zaidi, S., Herold, K. F., Milner, T. A., Hemmings, H. C., & Platholi, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.02.697407 · Cited by 1
“In the hippocampus, attenuation of resting NMDARs on CA1 glutamatergic neurons by ketamine or HNK enhances local BDNF translation through eukaryotic elongation factor 2 (eEF2) kinase-dependent pathways, thereby increasing synaptic drive and homeostatic plasticity 7, 68, 69 .”
InfluentialAksoy, A., Kurutas, E. B., & DEMİRHAN, İ. (2026) · Journal of Basic and Clinical Health Sciences · doi:10.30621/jbachs.1654813
La kétamine, un antidépresseur d'action rapide et antagoniste du récepteur NMDA du glutamate
Nguyen, T. M. L. (2023) · theses.fr (ABES) · doi:10.70675/0ba94412ze24bz4514z9262z9ace4cb240c9
Zhang, B., & Li, C. (2026) · Depression and Anxiety · doi:10.1155/da/1891046
“…this inhibitory effect may be mediated by eukaryotic elongation factor 2 (eEF2) signaling, given that spontaneous synaptic NMDA blockade exerted antidepressant action via suppressing eEF2 phosphorylation at threonine 56, which ultimately enhanced BDNF expression [125, 127, 143] (Figure 2C7).”
Metadata
- Authors
- Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Monteggia, Lisa M.
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7659
- Pages
- E1-E3
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2631673659
- Cited by
- 180
- References
- 13
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 10 · 2023: 11 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 36 · 2017: 15
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine metabolites, hydroxynorketamine, NMDA receptor, synaptic plasticity, antidepressant effects, depression, rapid antidepressant response, spontaneous neurotransmission, glutamate release, memantine, age dependence, intraperitoneal administration, synaptic potentiation, depression biomarkers, depression remission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.